evidence table

Cocoa Flavanol Blood Pressure Randomized Trial Evidence Table

Name: Cocoa Flavanol Blood Pressure Randomized Trial Evidence Table
Creator: Migaku
License: https://creativecommons.org/licenses/by/4.0/

Structured evidence table for Cocoa Flavanol Blood Pressure Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topic	claim	evidence level	citation	source
Cocoa Flavanol Blood Pressure Randomized Trial	Among the different forms of the disease, type 2 diabetes mellitus (T2D) accounts for approximately 90–95% of all cases and is strongly associated with insulin resistance, excess adiposity, physical inactivity, and dietary patterns characterized by high consumption of energy-dense, highly processed foods [,].	3	Tornero-Aguilera Jose Francisco (2026)	Cocoa-Based Plant Matrices in Glucose Metabolism: Bioactive Compounds and Redox Signaling
Cocoa Flavanol Blood Pressure Randomized Trial	6 7 8 Over the past decades, the prevalence of diabetes has increased markedly worldwide, reaching levels of major public health concern.	3	Tornero-Aguilera Jose Francisco (2026)	Cocoa-Based Plant Matrices in Glucose Metabolism: Bioactive Compounds and Redox Signaling
Cocoa Flavanol Blood Pressure Randomized Trial	The disease imposes a substantial economic burden on healthcare systems, reduces quality of life, and is associated with a marked increase in mortality risk.	3	Tornero-Aguilera Jose Francisco (2026)	Cocoa-Based Plant Matrices in Glucose Metabolism: Bioactive Compounds and Redox Signaling
Cocoa Flavanol Blood Pressure Randomized Trial	1 2 3 4 5 Diabetes mellitus comprises a complex and heterogeneous group of metabolic disorders characterized by chronic hyperglycemia resulting from alterations in insulin secretion, insulin action, or a combination of both processes.	3	Tornero-Aguilera Jose Francisco (2026)	Cocoa-Based Plant Matrices in Glucose Metabolism: Bioactive Compounds and Redox Signaling
Cocoa Flavanol Blood Pressure Randomized Trial	MetS is a multifactorial condition, with its primary indicators including obesity, hypertension, dyslipidemia, insulin resistance, and hyperglycemia; i.e., a patient who possesses at least 3 of the following parameters is designated with MetS: glucose intolerance, increased levels of triglycerides, augmented waist circumference, low levels of high-density lipoprotein cholesterol (HDL-c), and hypertension [,,].	3	Tomaru Júlia Mayumi (2026)	Beyond Taste: The Impact of Chocolate on Cardiovascular and Steatotic Liver Disease Risk Factors
Cocoa Flavanol Blood Pressure Randomized Trial	It is possible to develop a close relationship with MetS, metabolic dysfunction-associated steatotic liver disease (MASLD), and CVD [,].	3	Tomaru Júlia Mayumi (2026)	Beyond Taste: The Impact of Chocolate on Cardiovascular and Steatotic Liver Disease Risk Factors
Cocoa Flavanol Blood Pressure Randomized Trial	MASLD is strongly associated with various conditions, including MetS, and is characterized by the persistence of a chronic inflammatory state detrimental to the organism [,].	3	Tomaru Júlia Mayumi (2026)	Beyond Taste: The Impact of Chocolate on Cardiovascular and Steatotic Liver Disease Risk Factors
Cocoa Flavanol Blood Pressure Randomized Trial	1 2 3 4 5 6 7 8 9 10 11 12 13 14 Metabolic disorders are increasing sharply due to severe modifications in lifestyle [,,,].	3	Tomaru Júlia Mayumi (2026)	Beyond Taste: The Impact of Chocolate on Cardiovascular and Steatotic Liver Disease Risk Factors